Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul;15(7):542-544.
doi: 10.1111/1753-0407.13434. Epub 2023 Jun 13.

A diabetes update

Zachary Bloomgarden  1
Affiliations
Editorial

A diabetes update

Zachary Bloomgarden. J Diabetes. 2023 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023;14:1161521. - PMC - PubMed
    1. Prattichizzo F, Frigé C, La Grotta R, Ceriello A. Weight variability and diabetes complications. Diabetes Res Clin Pract. 2023;199:110646. doi:10.1016/j.diabres.2023.110646 - DOI - PubMed
    1. Tschöp M, Nogueiras R, Ahrén B. Gut hormone‐based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023. doi:10.1007/s00125-023-05929-0 - DOI - PMC - PubMed
    1. Pedersen SD, Giorgino F, Umpierrez G, et al. Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme. Diabetes Obes Metab. 2023. doi:10.1111/dom.15140 - DOI - PubMed
    1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205‐216. doi:10.1056/NEJMoa2206038 - DOI - PubMed

Publication types